SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321333.
  • 2
    Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D 1996 Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative. Control Clin Trials 17: 509525.
  • 3
    Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523534.
  • 4
    Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD 2002 Postmenopausal hormone replacement therapy: Scientific review. JAMA 288: 872881.
  • 5
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282: 637645.
  • 6
    Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H III, Gennari C, Christiansen C, Arnaud CD, Delmas PD 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch Intern Med 160: 34443450.
  • 7
    Cummings S, Eckert S, Krueger K, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 21892197.
  • 8
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 65: 125134.
  • 9
    Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87: 36093617.
  • 10
    Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD 2002 Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287: 847857.
  • 11
    Neven P, Goldstein SR, Ciaccia AV, Zhou L, Silfen SL, Muram D 2002 The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 85: 388390.
  • 12
    Rautaharju PM, Calhoun HP, Chaitman BR 1992 NOVACODE serial ECG classification system for clinical trials and epidemiologic studies. J Electrocardiol 24 (Suppl): 179187.
  • 13
    World Health Organization 1995 A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception. J Clin Epidemiol 48: 15131547.
  • 14
    Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 290: 17291738.
  • 15
    Jorgensen L, Engstad T, Jacobsen BK 2001 Bone mineral density in acute stroke patients: Low bone mineral density may predict first stroke in women. Stroke 32: 4751.
  • 16
    Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV 1998 Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 62: 209213.
  • 17
    Tanko LB, Bagger YZ, Christiansen C 2003 Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73: 1520.
  • 18
    Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR 1999 Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 130: 270277.
  • 19
    Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, Cauley JA, Cummings SR 2001 Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol 19: 31113116.
  • 20
    Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA 2002 Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287: 216220.
  • 21
    Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG 2003 Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348: 18391854.
  • 22
    Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL 2000 Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: A placebo-controlled randomized trial. Obstet Gynecol 96: 359365.
  • 23
    National Cancer Institute 2000 Surveillance, epidemiology, and end result (SEER) cancer statistics review, 1975–2000. Available online at http://seer.cancer.gov/csr/1975_2000. Accessed on January 6, 2004.
  • 24
    Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH 1999 Beta-carotene supplementation and incidence of cancer and cardiovascular disease: The Women's Health Study. J Natl Cancer Inst 91: 21022106.
  • 25
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 16151622.
  • 26
    Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ 2000 A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933941.
  • 27
    Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW 2001 Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88: 392395.
  • 28
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N 2002 The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 3: 153159.